Health Care [ 9/12 ] | Biotechnology [ 61/74 ]
NASDAQ | Common Stock
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of radioimmunotherapy and antibody based therapeutic products for the treatment of cancer.
It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.
The company also develops DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumors; and Omburtamab, an antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma.
In addition, it engages in the development of CD38-SADA and GD2-GD3 Vaccine; and offers self-assembly disassembly pretargeted radioimmuno therapy (SADA PRIT) technology platform to deliver the radioactive payload to the tumor.
The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products.
It operates in the United States, Western Europe, Eastern Asia, Latin America, Western Asia, and internationally.
Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in Princeton, New Jersey.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 26, 25 | -0.15 Decreased by -650.00% | -0.13 Decreased by -13.64% |
| Nov 8, 24 | -0.16 Increased by +11.11% | -0.15 Decreased by -6.67% |
| Aug 12, 24 | -0.21 Decreased by -50.00% | -0.13 Decreased by -61.54% |
| May 7, 24 | -0.15 Increased by 0.00% | -0.14 Decreased by -7.14% |
| Feb 29, 24 | -0.02 Decreased by -166.67% | -0.20 Increased by +90.00% |
| Nov 13, 23 | -0.18 Increased by +71.43% | -0.19 Increased by +5.26% |
| Aug 10, 23 | -0.14 Increased by +85.11% | -0.24 Increased by +41.67% |
| May 8, 23 | -0.15 Increased by +76.56% | -0.32 Increased by +53.13% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 26.50 M Increased by +32.93% | -6.79 M Decreased by -2.43% | Decreased by -25.63% Increased by +22.95% |
| Dec 31, 24 | 26.50 M Increased by +13.41% | -6.79 M Decreased by -587.25% | Decreased by -25.63% Decreased by -506.01% |
| Sep 30, 24 | 18.46 M Decreased by -9.74% | -7.00 M Increased by +9.67% | Decreased by -37.91% Decreased by -0.08% |
| Jun 30, 24 | 22.80 M Increased by +9.86% | -9.25 M Decreased by -46.76% | Decreased by -40.57% Decreased by -33.59% |
| Mar 31, 24 | 19.93 M Decreased by -1.58% | -6.63 M Decreased by -30.06% | Decreased by -33.26% Decreased by -32.15% |
| Dec 31, 23 | 23.36 M Decreased by -25.71% | -988.00 K Decreased by -185.39% | Decreased by -4.23% Decreased by -214.94% |
| Sep 30, 23 | 20.45 M Increased by +63.15% | -7.75 M Increased by +73.32% | Decreased by -37.88% Increased by +83.65% |
| Jun 30, 23 | 20.75 M Increased by +92.19% | -6.30 M Increased by +85.11% | Decreased by -30.37% Increased by +92.25% |